Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients

Deng, Qiu-Kui; Lei, Yonggang; Lin, Ying‐Li; Ma, Jun

doi:10.12659/msm.897179

Cited by 30 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, the data were obtained from patients treated at a single center in China, which limits the generalizability of the results to the wider population. Finally, of course, the present study only examined factors that are routinely assessed in the clinical management of PCa, but novel markers such as aberrant DNA methylation [ 40 , 41 ], miRNA expression [ 42 ], and genes involved in inflammation [ 43 ] are promising and should be examined in future studies. Multicenter prospective studies including larger sample sizes are required to confirm the conclusions of this study.…”

Section: Discussionmentioning

confidence: 99%

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma

et al. 2017

View full text Add to dashboard Cite

BackgroundProstate carcinoma (PCa) is often not diagnosed until advanced disease with bone metastasis. Predictive factors for bone metastasis are required to improve patient outcomes. The study aimed to analyze the factors associated with bone metastases in newly diagnosed patients with PCa.Material/MethodsThis was a retrospective study of 80 patients newly diagnosed with PCa by pathological examination between January 2012 and December 2014. Bone metastases were diagnosed by positron emission computed tomography. Clinical data, serological laboratory results, and pathological examination results were collected.ResultsAmong the 80 patients, 45 (56%) had bone metastases. Age, serum alkaline phosphatase, prostate-specific antigen (PSA), erythrocyte sedimentation rate, PCa tissue Gleason score, androgen receptor (AR) expression, and Ki-67 expression were higher in patients with bone metastasis compared with those without (all P<0.05). Multivariate logistic regression showed that PSA (OR: 1.005; 95%CI: 1.001–1.010; P=0.016), Gleason score (OR: 4.095; 95%CI: 1.592–10.529; P=0.003), and AR expression (OR: 14.023; 95%CI: 3.531–55.6981; P=0.005) were independently associated with bone metastases. Cut-off values for PSA, Gleason score, and AR expression were 67.1 ng/ml (sensitivity: 55.6%; specificity: 97.1%), 7.5 (sensitivity: 75.6%; specificity: 82.9%), and 2.5 (sensitivity: 84.0%; specificity: 91.4%), respectively.ConclusionsPSA, Gleason score, and AR expression in PCa tissues were independently associated with PCa bone metastases. These results could help identifying patients with PCa at high risk of bone metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…One group of proteins whose altered expression has been associated with tumor invasiveness, metastatic dissemination, and poor patient prognosis is the cadherins superfamily. Cadherins are a large multigene family of transmembrane glycoproteins with a crucial role in homophilic cell-cell adhesion, cell polarity, cell proliferation, migration, and differentiation [17,18]. E-Cadherin has been considered the paradigmatic classical cadherin and is mainly expressed in epithelial tissues.…”

Section: Metodologiamentioning

confidence: 99%

Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features

et al. 2018

View full text Add to dashboard Cite

Cadherins seem to play and important role in prostate cancer (PCa) progression. E-cadherin loss of expression has been associated with poor prognosis; P-cadherin's role is still elusive. Although pT3 PCa is often considered "high-risk cancer," it does not exhibit an uniformly poor prognosis. Herein, we assessed the prognostic value and survival impact of E-cadherin and P-cadherin immunoexpression in pT3 PCa. Radical prostatectomy (RP) specimens from 102 pT3 PCa patients treated between 1991 and 2014 in a single institution were designated for E-cadherin and P-cadherin immunoexpression analysis. A representative block from each specimen was selected for tissue micro-array (TMA) construction, using 3 cores per case. E-cadherin immunoexpression was assessed via a digital image analysis system. For P-cadherin, scoring criteria for HER2 in gastric cancer were used. Clinical records of all patients were reviewed for baseline clinical/pathologic characteristics and follow-up data. E-cadherin-low PCa patients displayed worse disease-specific survival (DSS), although not reaching statistical significance (HR 2.65, 95%CI 0.81-7.88). However, considering the pT3b group only, those with low E-cadherin immunoexpression displayed significantly worse overall-survival (OS) and DSS (HR 3.69, 95%CI 1.18-11.50; HR 5.90, 95%CI 1.40-24.81). No significant differences in survival were found for P-cadherin differential immunoexpression. Furthermore, an association between E-cadherin and P-cadherin immunoexpression (p = 0.019) was found, as among E-cadherin-low PCa, 96.6% were P-cadherin negative. We demonstrated that low E-cadherin immunoexpression discriminates among pT3b PCa patients those with poorer survival and which might benefit from specific therapy. The role of P-cadherin in PCa seems context-dependent deserving further investigation.

show abstract

“…Sunami et al reported that GSTP1 me , RASSF1A me and RARβ2 me associated with Gleason score and serum PSA levels, whereas GSTP1 me and RARβ2 me also associated with advanced stages of disease [173]. Moreover, individually, serum PCDH17 me , PCDC10 me and PCDH8 me were also associated with advanced clinical stage, higher preoperative serum PSA, as well as lymph node metastasis and shorter biochemical recurrence-free survival [193][194][195]. Besides being also associated with Gleason score, advanced tumor stage and high PSA, CDH13 me was further associated with shorter OS [183].…”

Section: Prognosis Predicition and Monitoringmentioning

confidence: 99%

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types

Constâncio

Nunes

Henrique

et al. 2020

Cells

141

117

View full text Add to dashboard Cite

Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal population-based cancer screening methods remain an unmet need, since cancer detection at early stages increases the prospects of successful and curative treatment, leading to a lower incidence of recurrences. Moreover, the current parameters for cancer patients’ stratification have been associated with divergent outcomes. Therefore, new biomarkers that could aid in cancer detection and prognosis, preferably detected by minimally invasive methods are of major importance. Aberrant DNA methylation is an early event in cancer development and may be detected in circulating cell-free DNA (ccfDNA), constituting a valuable cancer biomarker. Furthermore, DNA methylation is a stable alteration that can be easily and rapidly quantified by methylation-specific PCR methods. Thus, the main goal of this review is to provide an overview of the most important studies that report methylation biomarkers for the detection and prognosis of the four major cancers after a critical analysis of the available literature. DNA methylation-based biomarkers show promise for cancer detection and management, with some studies describing a “PanCancer” detection approach for the simultaneous detection of several cancer types. Nonetheless, DNA methylation biomarkers still lack large-scale validation, precluding implementation in clinical practice.

show abstract

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients

Cited by 30 publications

References 36 publications

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma

Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types

Contact Info

Product

Resources

About